Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Non-Current Liabilities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other Non-Current Liabilities for 13 consecutive years, with $313000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 93.71% to $313000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $313000.0, a 93.71% decrease, with the full-year FY2024 number at $1.9 million, changed N/A from a year prior.
  • Other Non-Current Liabilities was $313000.0 for Q3 2025 at Theravance Biopharma, down from $1.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $76.0 million in Q4 2022 to a low of $313000.0 in Q3 2025.
  • A 5-year average of $11.4 million and a median of $2.6 million in 2021 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: soared 2303.22% in 2022, then plummeted 93.71% in 2025.
  • Theravance Biopharma's Other Non-Current Liabilities stood at $2.6 million in 2021, then skyrocketed by 2812.96% to $76.0 million in 2022, then tumbled by 89.9% to $7.7 million in 2023, then crashed by 75.39% to $1.9 million in 2024, then crashed by 83.44% to $313000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Other Non-Current Liabilities are $313000.0 (Q3 2025), $1.5 million (Q2 2025), and $1.3 million (Q1 2025).